After another successful #AASLD, we look ahead to next week when our team will be heading to London for Jefferies and London Life Sciences Week. Our CFO Lucy Singah and VP Strategy & Operations Victor Dillard will be there – reach out to set up a meeting!

We are thrilled to announce new clinical and preclinical data to be presented at the @AASLDtweets The Liver Meeting® 2025 The data strongly supports the hypothesis that RMT has anti-inflammatory and anti-fibrotic effects in cirrhosis. Full PR here: https://t.co/Yponcg3BN8

We are proud to share that @ResolutionTx has been named a finalist in two categories at the 2025 @lifestarsawards! ⭐ Our CEO Amir Hefni has been shortlisted for CEO of the Year, while Resolution is a finalist for ‘Series B Raise of the Year’! #OneTeam #LifestarsAwards

We are pleased to announce that @ResolutionTx has had two abstracts selected for presentation at the @AASLDtweets ‘The Liver Meeting’ in Washington D.C., from the 7 - 11 November. For full details, see the press release here: https://t.co/zF6Vo56i4n

This week, @ResolutionTx will be attending and presenting at the BASL annual meeting 2025 in Belfast, Northern Ireland. Professor @JAFallowfield, will present a poster detailing the study protocol for the Phase I/II EMERALD study of RTX001. Press release: https://t.co/y5mS3Ze1nb

At @ResolutionTx, we 've got a busy start to the conference season! Our team members will be attending and presenting at multiple conferences in October. Visit our LinkedIn for more details and do get in touch to connect at these events: https://t.co/HI1ZxFKIrR

👉 En Resolution Therapeutics trabajan con macrófagos para tratar a pacientes en riesgo de descompensación hepática Más en nuestra web ⤵️ https://t.co/vc2CCbRon1 🤝 Una colaboración de FNETH y @ResolutionTx  #FNETH #ResolutionTherapeutics #Health #ClinicalTrial

This week @ResolutionTx unveiled our EMERALD HEROES TILE to our wall of pride in both our London and Edinburgh offices. This celebrates the dosing of the first patient in the Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease. #OneTeam

We are about to go LIVE! Join us TODAY at 14.00 BST for a virtual R&D webinar discussing our regenerative macrophage therapies to treat inflammatory and fibrotic diseases with world leading hepatologists @JAFallowfield and @ebtapper Register here:

🎥Don’t miss our virtual R&D webinar TOMORROW at 14:00 BST with world leading hepatologists @JAFallowfield and @ebtapper This webinar will be a fantastic opportunity to explore the current treatment landscape for end-stage liver disease. Register here:

🎥 Join us on Wednesday at 14.00 BST for a virtual R&D webinar! Hear from our senior leadership team, alongside chief Investigator of the Phase 1/2 EMERALD study, @JAFallowfield , and esteemed hepatologist, @ebtapper. Register here: https://t.co/dSVbCvslde

📢 Don't miss @ResolutionTx's virtual R&D webinar next Wednesday! Join to hear presentations from the senior leadership team and world leading clinical hepatologists @ebtapper and @JAFallowfield. Register for the webinar here: https://t.co/dSVbCvrNnG

Today @ResolutionTx is pleased to announce the appointment of Lucy Singah as CFO and Daniel Kennedy as CBO. Lucy joins to drive corporate and strategic goals, and Daniel will drive business development and partnering deals. #appointment #CFO #CBO #ONETEAM

@ResolutionTx announces today that the first patient has been dosed and safety cleared in its Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease. The study is now open for full enrolment in the UK and Spain Read the press release below.

📢 @ResolutionTx to host virtual R&D webinar on 17 September at 14:00 BST alongside world leading clinical hepatologists @ebtapper and @JAFallowfield Register here: https://t.co/DKj77WE8wK Read the press release here: https://t.co/mziUpdkZIf

@ResolutionTx VP Clinical Operations Esther Kitto will be in Munich, Germany this week from May 21-22 for the 19th Clinical Trials Strategic Summit! Be sure to reach out to Esther to connect, and catch her presentation if you're also in Munich!

@ResolutionTx has announced two data presentations at #ASGCT in New Orleans, US, May 13-17, 2025! The team will deliver insights from a proprietary ex vivo RMT manufacturing process and a candidate testing suite. Read more: https://t.co/zeW42K2Ap6 #ESLD #ASGCT2025 #CellTherapy

Catch Victor Dillard, VP Strategy and Operations in Bruges for this year's Bio€quity Europe. Victor will be delivering a company presentation, where you can learn more about our approach to pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases.

Next week marks the beginning of the @EASLnews Congress, this year being held in Amsterdam, The Netherlands, between May 7-10, 2025. Reach out to the @ResolutionTx team who will be attending the conference! #RMT #EASLCongress #liverdisease

Resolution is excited to present at next month's #ASGCT in New Orleans, US, between May 13-17, 2025! Members of the Resolution team will be delivering two presentations on key new data, watch the below for details. If you will be in Louisiana get in touch to connect!